TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Brief Summary: This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.

Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be randomized 2:1 to receive either apremilast 30 mg twice daily (BID) or placebo for the first 16 weeks.


Options:
A: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Apremilast 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Apremilast 30 mg BID, Placebo
C: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab
D: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ixekizumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ixekizumab, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electronic Alert System Combined With a Risk Score Calculation Tool for Improving Appropriate Thromboprophylaxis in Hospitalized Medical Patients: a Randomized Controlled Trial
Brief Summary: The investigators aim to investigate whether a computer-based alert system in the electronic patient chart and order entry system using the Geneva Risk Score as clinical decision support tool to estimate the risk of venous thromboembolism improves the rate of appropriate thromboprophylaxis among hospitalized medical patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
B: Arm Label: mHealth midwives; Type: EXPERIMENTAL; Interventions: Device: mHealth | Arm Label: mHealth midwives - control; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Arm Label: Pregnant Women; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Intervention Type: DEVICE; Name: mHealth; Assigned to Arm(s): Pregnant Women, mHealth midwives, mHealth midwives - control
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HIT Intervention without feedback; Type: EXPERIMENTAL; Interventions: Other: 3-Part Intervention | Arm Label: HIT Intervention with feedback; Type: EXPERIMENTAL; Interventions: Other: 4-Part Intervention | Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Other: 1-part intervention | Intervention Type: OTHER; Name: 3-Part Intervention; Assigned to Arm(s): HIT Intervention without feedback | Intervention Type: OTHER; Name: 4-Part Intervention; Assigned to Arm(s): HIT Intervention with feedback | Intervention Type: OTHER; Name: 1-part intervention; Assigned to Arm(s): Feedback only
D: Arm Label: Alert Group; Type: EXPERIMENTAL; Interventions: Other: Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart; Assigned to Arm(s): Alert Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea?
Brief Summary: Our aim is to evaluate and compare the pain relief of estradiol valerate/dienogest and ethinylestradiol/ drospirenone by using doppler indices.

100 nullipara patients with symptoms of severe primary dysmenorrhea (PD) requesting contraception aged from 18 to 35 were included to the study. Visual analog scale (VAS), the uterine artery doppler indices including systole/diastole rates ( S/D), pulsatility index (PI) and resistance index (RI) values were evaluated and recorded in both uterine vessels before treatment. The 66 PD patients who met the inclusion criteria were divided into 2 groups and 33 healthy controls created Group 1. Group 2 were administered estradiol valerate/dienogest while Group 3 were administered 0.03 mg ethinylestradiol and 3 mg drospirenone. Both VAS scores and doppler indices were repeated after 3 months treatment. The changes in values were recorded.


Options:
A: Arm Label: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Drug: Placebo Match to SH T00658ID | Arm Label: Ethinyl estradiol, Levonorgestrel (Miranova); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ethinyl estradiol, Levonorgestrel (Miranova), Drug: Placebo Match to SH D593B | Intervention Type: DRUG; Name: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Ethinyl estradiol, Levonorgestrel (Miranova); Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova) | Intervention Type: DRUG; Name: Placebo Match to SH T00658ID; Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo Match to SH D593B; Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova)
B: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Qlarista Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol valerate/dienogest | Arm Label: Yasmin Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ethinylestradiol and drospirenone | Intervention Type: DRUG; Name: estradiol valerate/dienogest; Assigned to Arm(s): Qlarista Group | Intervention Type: DRUG; Name: ethinylestradiol and drospirenone; Assigned to Arm(s): Yasmin Group
D: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Professional Coaching on Early Career Academic Emergency Physician Well-Being, Burnout, Leadership Strengths, and Goal Attainment: A Pilot Randomized, Controlled Trial
Brief Summary: This research study is designed to answer the question: How does professional coaching impact early career academic emergency medicine physician goal attainment, leadership strengths, well-being, and burnout?


Options:
A: Arm Label: Staff of facilities for intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated leading, managing and governing for results model | Arm Label: Staff of facilities for control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional model | Intervention Type: BEHAVIORAL; Name: Integrated leading, managing and governing for results model; Assigned to Arm(s): Staff of facilities for intervention | Intervention Type: BEHAVIORAL; Name: Traditional model; Assigned to Arm(s): Staff of facilities for control
B: Arm Label: Educational Intervention; Type: EXPERIMENTAL; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Intervention Type: OTHER; Name: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance; Assigned to Arm(s): CONTROL, Educational Intervention
C: Arm Label: Retreat; Type: EXPERIMENTAL; Interventions: Other: Retreat | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Retreat; Assigned to Arm(s): Retreat
D: Arm Label: One-to-One Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Professional coaching | Arm Label: Group Coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Professional coaching | Arm Label: Group Coaching Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Professional coaching; Assigned to Arm(s): Group Coaching, One-to-One Coaching

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Brief Summary: This is a randomized comparative trial investigating two different catheter management strategies among post-gynecologic surgery patients. Women undergoing any benign gynecologic surgery wherein they are anticipated to stay at least overnight and in whom no prolapse or urinary tract surgery was concurrently performed, will be randomly assigned to either conventional urinary catheter care removal on post-operative day 1 or same day surgery urinary catheter removal. Patient satisfaction and lower urinary tract symptoms including urine culture and antibiotic use will be tracked across both cohorts over the 2 weeks following the index surgery.


Options:
A: Arm Label: Conventional Foley Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Fast Tract Foley care; Type: EXPERIMENTAL; Interventions: Other: Fast Track foley removal | Intervention Type: OTHER; Name: Fast Track foley removal; Assigned to Arm(s): Fast Tract Foley care
B: Arm Label: Study group 1; Type: EXPERIMENTAL; Interventions: Other: Removal of urethral catheter | Arm Label: Study group 2; Type: OTHER; Interventions: Other: Removal of urethral catheter | Intervention Type: OTHER; Name: Removal of urethral catheter; Assigned to Arm(s): Study group 1, Study group 2
C: Arm Label: Early (within 48 hours of surgery); Type: N/A; Interventions: N/A | Arm Label: Late (6 hours after epidural removal); Type: N/A; Interventions: N/A
D: Arm Label: Immediate catheter removal; Type: EXPERIMENTAL; Interventions: Procedure: Immediate catheter removal | Arm Label: Post op day 1 catheter removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Post op day 1 catheter removal | Intervention Type: PROCEDURE; Name: Immediate catheter removal; Assigned to Arm(s): Immediate catheter removal | Intervention Type: PROCEDURE; Name: Post op day 1 catheter removal; Assigned to Arm(s): Post op day 1 catheter removal

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia
Brief Summary: To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium \[S-K\] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).


Options:
A: Arm Label: Sodium Zirconium Cyclosilicate (SZC); Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (SZC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sodium zirconium cyclosilicate 10 g three times daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Placebo once daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sodium zirconium cyclosilicate 5 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 10 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 15 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Intervention Type: DRUG; Name: Sodium zirconium cyclosilicate; Assigned to Arm(s): Sodium zirconium cyclosilicate 10 g once daily, Sodium zirconium cyclosilicate 10 g three times daily, Sodium zirconium cyclosilicate 15 g once daily, Sodium zirconium cyclosilicate 5 g once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo once daily
C: Arm Label: Patiromer; Type: ACTIVE_COMPARATOR; Interventions: Drug: Patiromer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Sodium Zirconium Cyclosilicate (ZS) 5g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 5g | Arm Label: Sodium Zirconium Cyclosilicate (ZS) 10g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 10g | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 5g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 5g | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 10g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 10g | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Mobile Phone-based Telemonitoring Application for Self-management and Clinical Decision Support for Patients With Complex Chronic Conditions
Brief Summary: Remote patient monitoring is a potential component for the management of chronic conditions that may provide reliable and real-time physiological measurements for clinical decision support, alerting, and patient self-management. The purpose of this study is to evaluate an UHN-built remote monitoring system for patients with complex chronic conditions called Medly.


Options:
A: Arm Label: Inpatient hospitalization; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional inpatient hospitalization | Arm Label: Home hospitalization; Type: EXPERIMENTAL; Interventions: Other: Home hospitalization | Intervention Type: OTHER; Name: Home hospitalization; Assigned to Arm(s): Home hospitalization | Intervention Type: OTHER; Name: Traditional inpatient hospitalization; Assigned to Arm(s): Inpatient hospitalization
B: Arm Label: Cognitive Behavioral Therapy (CBT-I); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia | Arm Label: CBT-I + COPD-ED; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia, Behavioral: COPD Education | Arm Label: COPD Education (COPD-ED); Type: EXPERIMENTAL; Interventions: Behavioral: COPD Education | Arm Label: Attention Control (AC); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Insomnia; Assigned to Arm(s): CBT-I + COPD-ED, Cognitive Behavioral Therapy (CBT-I) | Intervention Type: BEHAVIORAL; Name: COPD Education; Assigned to Arm(s): CBT-I + COPD-ED, COPD Education (COPD-ED) | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention Control (AC)
C: Arm Label: Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen
D: Arm Label: Telemonitoring (Medly); Type: EXPERIMENTAL; Interventions: Device: Medly | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Medly; Assigned to Arm(s): Telemonitoring (Medly)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Expanding Access to Home-Based Palliative Care Through Primary Care Medical Groups
Brief Summary: This study will test the effectiveness of integrating an evidence-based model of home-based palliative (HBPC) within primary care clinics on patient and caregiver outcomes. The investigators will conduct a randomized controlled trial, randomizing 1,155 seriously ill patients (and approximately 884 family caregivers) who receive primary care from 30-40 regional accountable care organizations (ACOs) in California to one of two study groups: HBPC or enhanced usual care (EUC). Follow-up data will be collected via telephone surveys with patients at 1- and 2-months and with caregivers at 1- and 2-months, and, as appropriate, following the death of the patient.


Options:
A: Arm Label: Usual Care + Transitional Care Model; Type: EXPERIMENTAL; Interventions: Behavioral: Transitional Care Model, Behavioral: Usual care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Transitional Care Model; Assigned to Arm(s): Usual Care + Transitional Care Model | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care, Usual Care + Transitional Care Model
B: Arm Label: Home-based Palliative Care; Type: EXPERIMENTAL; Interventions: Other: Home-based palliative care | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: OTHER; Name: Home-based palliative care; Assigned to Arm(s): Home-based Palliative Care | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced Usual Care
C: Arm Label: Integrated care; Type: EXPERIMENTAL; Interventions: Other: Integrated care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated care; Assigned to Arm(s): Integrated care | Intervention Type: OTHER; Name: Integrated care; Assigned to Arm(s): Integrated care
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: OTHER; Interventions: Other: Transition program | Intervention Type: OTHER; Name: Transition program; Assigned to Arm(s): Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
Brief Summary: The Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM) study is the first placebo-controlled randomized clinical trial of hydroxyurea treatment in a malaria endemic region. NOHARM has now achieved full enrollment; all children have completed the blinded portion of the protocol and are in the open-label study treatment portion.

This extension study of maximum tolerated dose (MTD), addresses the next critical set of questions about the optimal dosing and monitoring of hydroxyurea treatment for children with SCA in low-resource settings. By providing guidance about optimal hydroxyurea treatment, the NOHARM MTD Study will directly inform policies that can transform the health of African children living with SCA.


Options:
A: Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm
B: Arm Label: cohort 1 PF-04447943; Type: EXPERIMENTAL; Interventions: Drug: PDE9i | Arm Label: cohort 2 PF-04447943; Type: EXPERIMENTAL; Interventions: Drug: PDE9i | Arm Label: placebo comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for PDE9i | Arm Label: optional cohort of PF-04447943; Type: EXPERIMENTAL; Interventions: Drug: PDE9i | Intervention Type: DRUG; Name: PDE9i; Assigned to Arm(s): cohort 1 PF-04447943, optional cohort of PF-04447943 | Intervention Type: DRUG; Name: PDE9i; Assigned to Arm(s): cohort 2 PF-04447943, optional cohort of PF-04447943 | Intervention Type: DRUG; Name: placebo for PDE9i; Assigned to Arm(s): placebo comparator | Intervention Type: DRUG; Name: PDE9i; Assigned to Arm(s): optional cohort of PF-04447943
C: Arm Label: MTD Dose Escalation; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Fixed Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Fixed Dose, MTD Dose Escalation
D: Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C